These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 22214393)

  • 21. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
    Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
    Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Navigating patients and caregivers through the course of Alzheimer's disease.
    Aupperle PM
    J Clin Psychiatry; 2006; 67 Suppl 3():8-14; quiz 23. PubMed ID: 16649846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
    Jönsson L
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discontinuing Alzheimer's disease drug therapy: why, when, and how.
    Crutchfield D
    Director; 2008; 16(1):19-21. PubMed ID: 19343870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prescribing of drugs for Alzheimer's disease: a South African database analysis.
    Truter I
    Int Psychogeriatr; 2010 Mar; 22(2):264-9. PubMed ID: 20067653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug therapy of dementia in elderly patients. A review.
    Olsen CE; Poulsen HD; Lublin HK
    Nord J Psychiatry; 2005; 59(2):71-7. PubMed ID: 16195103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Memantine for treatment of moderate to severe Alzheimer's disease.
    Perras C
    Issues Emerg Health Technol; 2005 Mar; (64):1-4. PubMed ID: 15762015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Donepezil and Alzheimer's dementia.
    Earl-Slater A; Walley T
    Clin Perform Qual Health Care; 2000; 8(1):47-51. PubMed ID: 11183967
    [No Abstract]   [Full Text] [Related]  

  • 32. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
    Sakka P; Tsolaki M; Hort J; Hager K; Soininen H; López Pousa S; Li C; Schwam E
    Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Donepezil use in managed Medicare: effect on health care costs and utilization.
    Fillit H; Gutterman EM; Lewis B
    Clin Ther; 1999 Dec; 21(12):2173-85. PubMed ID: 10645761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain.
    Antonanzas F; Rive B; Badenas JM; Gomez-Lus S; Guilhaume C
    Eur J Health Econ; 2006 Jun; 7(2):137-44. PubMed ID: 16670912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2012 Alzheimer's disease facts and figures.
    Alzheimer's Association
    Alzheimers Dement; 2012; 8(2):131-68. PubMed ID: 22404854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
    Prasher VP
    Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How do we treat people with dementia in Croatia.
    Mimica N; Presecki P
    Psychiatr Danub; 2010 Jun; 22(2):363-6. PubMed ID: 20562784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
    Bullock R
    Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
    Feldman HH; Schmitt FA; Olin JT;
    Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study.
    Matsuzono K; Hishikawa N; Ohta Y; Yamashita T; Deguchi K; Nakano Y; Abe K
    J Alzheimers Dis; 2015; 45(3):771-80. PubMed ID: 25624417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.